MX386776B - Composiciones de células t deficientes del receptor de células t. - Google Patents
Composiciones de células t deficientes del receptor de células t.Info
- Publication number
- MX386776B MX386776B MX2019007492A MX2019007492A MX386776B MX 386776 B MX386776 B MX 386776B MX 2019007492 A MX2019007492 A MX 2019007492A MX 2019007492 A MX2019007492 A MX 2019007492A MX 386776 B MX386776 B MX 386776B
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- tcr
- deficient
- cell
- compositions
- Prior art date
Links
- 230000002950 deficient Effects 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 7
- 208000037765 diseases and disorders Diseases 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un método para producir una célula T humana modificada genéticamente, caracterizado porque comprende expresar una molécula inhibidora de TCR (TIM) en la célula T, en donde la TIM está codificada por una secuencia de ácido nucleico seleccionada de SEQ ID NO: 80, 82, 84, o 86, una célula o células T humana modificada genéticamente producida por el método, una composición farmacéutica que comprende dichas células, un vector y una célula T humana que expresan el polipéptido SEQ ID NO: M811, 83, 85 o 87.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/459,664 US9273283B2 (en) | 2009-10-29 | 2012-04-30 | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| PCT/US2013/038921 WO2013166051A1 (en) | 2012-04-30 | 2013-04-30 | T cell receptor-deficient t cell compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019007492A MX2019007492A (es) | 2019-09-06 |
| MX386776B true MX386776B (es) | 2025-03-19 |
Family
ID=49515059
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007492A MX386776B (es) | 2012-04-30 | 2013-04-30 | Composiciones de células t deficientes del receptor de células t. |
| MX2014013118A MX366018B (es) | 2012-04-30 | 2013-04-30 | Composiciones de células t deficientes del receptor de células t. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013118A MX366018B (es) | 2012-04-30 | 2013-04-30 | Composiciones de células t deficientes del receptor de células t. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9273283B2 (es) |
| EP (3) | EP2844742B1 (es) |
| JP (2) | JP6411328B2 (es) |
| CN (3) | CN104395463B (es) |
| AU (2) | AU2013256424B2 (es) |
| BR (1) | BR112014027155B1 (es) |
| CA (1) | CA2871955C (es) |
| ES (2) | ES2878724T3 (es) |
| MX (2) | MX386776B (es) |
| RU (1) | RU2653761C2 (es) |
| WO (1) | WO2013166051A1 (es) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006036445A2 (en) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US12492376B2 (en) | 2009-10-29 | 2025-12-09 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| CN110511278B (zh) | 2012-05-07 | 2024-08-09 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
| ES2949648T3 (es) | 2012-12-20 | 2023-10-02 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| US9587237B2 (en) | 2013-03-14 | 2017-03-07 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| US9499855B2 (en) | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US10357515B2 (en) * | 2013-11-22 | 2019-07-23 | Cellectis | Method for generating batches of allogeneic T-cells with averaged potency |
| JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN107206024B (zh) | 2014-10-31 | 2021-12-03 | 宾夕法尼亚大学董事会 | 改变cart细胞中的基因表达及其用途 |
| BR112017011771A2 (pt) * | 2014-12-02 | 2018-07-10 | Prospect Chartercare Rwmc Llc | métodos e composições para o tratamento de câncer |
| IL253149B2 (en) | 2014-12-29 | 2023-11-01 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| SG11201706236SA (en) | 2015-02-06 | 2017-08-30 | Nat Univ Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| ES2983924T3 (es) | 2015-03-27 | 2024-10-28 | Immatics Biotechnologies Gmbh | Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| AU2016261600B2 (en) | 2015-05-08 | 2021-09-23 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
| AR105433A1 (es) | 2015-07-21 | 2017-10-04 | Novartis Ag | Métodos para mejorar la eficacia y expansión de las células inmunes |
| CN109824778B (zh) * | 2015-09-18 | 2022-07-19 | 上海科济制药有限公司 | 抗cd19全人抗体以及靶向cd19的免疫效应细胞 |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| HK1257295A1 (zh) | 2015-12-04 | 2019-10-18 | Novartis Ag | 用於免疫肿瘤学的组合物和方法 |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US20200255864A1 (en) * | 2016-03-19 | 2020-08-13 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| MA45478A (fr) * | 2016-04-11 | 2019-02-20 | Arbutus Biopharma Corp | Compositions de conjugués d'acides nucléiques ciblés |
| PT4180519T (pt) | 2016-04-15 | 2025-09-04 | Memorial Sloan Kettering Cancer Center | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados |
| AU2017261267B2 (en) | 2016-05-05 | 2023-01-05 | Southwest Research Institute | Three-dimensional bioreactor for cell expansion and related applications |
| CA2937157A1 (en) | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
| WO2018049095A1 (en) * | 2016-09-09 | 2018-03-15 | The Feinstein Institute For Medical Research | Methods of treating hypertension |
| KR20190062505A (ko) | 2016-10-03 | 2019-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Hpv-특이적 결합 분자 |
| CA3039774A1 (en) | 2016-10-10 | 2018-04-19 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
| AU2017363278B2 (en) | 2016-11-22 | 2022-10-27 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| EP3601561A2 (en) | 2017-03-22 | 2020-02-05 | Novartis AG | Compositions and methods for immunooncology |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| AU2018258045B2 (en) | 2017-04-26 | 2024-02-29 | Eureka Therapeutics, Inc. | Chimeric antibody/T-cell receptor constructs and uses thereof |
| EP3650545A4 (en) | 2017-06-20 | 2021-03-31 | Jiangsu Hengrui Medicine Co., Ltd. | METHOD OF TARGETING A TARGET CELL IN VITRO AND CRRNA USED IN THIS METHOD |
| EP3645036A1 (en) | 2017-06-30 | 2020-05-06 | Cellectis | Cellular immunotherapy for repetitive administration |
| AU2018313939A1 (en) | 2017-08-10 | 2020-02-06 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
| CA3076337A1 (en) | 2017-09-19 | 2019-03-28 | Massachusetts Institute Of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
| EP3692063A1 (en) | 2017-10-03 | 2020-08-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| WO2019071358A1 (en) * | 2017-10-12 | 2019-04-18 | Mcmaster University | Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF |
| JP2021505207A (ja) * | 2017-12-05 | 2021-02-18 | セリアド エス．アー．Ｃｅｌｙａｄ Ｓ．Ａ． | Ｎｋｇ２ｄベースの受容体を発現する免疫細胞のフラトリサイドの減少 |
| US12173316B2 (en) * | 2017-12-05 | 2024-12-24 | Celyad S.A | Compositions and methods for improving persistence of cells for adoptive transfer |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| JP7416695B2 (ja) | 2017-12-29 | 2024-01-17 | メモリアル スローン－ケタリング キャンサー センター | 増強されたキメラ抗原受容体およびその使用 |
| BR112020014913A2 (pt) | 2018-01-22 | 2020-12-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Métodos para uso de células t car |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| KR102828999B1 (ko) * | 2018-02-11 | 2025-07-04 | 메모리얼 슬로안 케터링 캔서 센터 | 비-hla 제한된 t 세포 수용체 및 이의 용도 |
| CN111918661A (zh) | 2018-02-21 | 2020-11-10 | 得克萨斯大学体系董事会 | 用于活化和扩增自然杀伤细胞的方法及其用途 |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| CN110343712B (zh) * | 2018-04-04 | 2023-12-26 | 达仁生物科技有限公司 | 嵌合抗原受体和其治疗肺癌的方法 |
| US11149244B2 (en) | 2018-04-04 | 2021-10-19 | Southwest Research Institute | Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy |
| KR102764123B1 (ko) | 2018-04-05 | 2025-02-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Τ 세포 수용체 및 이를 발현하는 조작된 세포 |
| CA3096458A1 (en) * | 2018-04-12 | 2019-10-17 | Umoja Biopharma, Inc. | Viral vectors and packaging cell lines |
| AU2019275076B2 (en) | 2018-05-23 | 2024-12-19 | National University Of Singapore | Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CN110616188B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种通用型car-t细胞及其制备方法和应用 |
| US12359169B2 (en) | 2018-06-20 | 2025-07-15 | Shanghai Longyao Biotechnology Inc., Ltd. | Universal CAR-T cell and preparation method and use thereof |
| SG11202012253WA (en) * | 2018-07-26 | 2021-01-28 | Nanjing Legend Biotech Co Ltd | Nef-containing t cells and methods of producing thereof |
| SG11202102986XA (en) | 2018-09-24 | 2021-04-29 | Southwest Res Inst | Three-dimensional bioreactors |
| CA3113618A1 (en) | 2018-09-28 | 2020-04-02 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| CN111788302A (zh) * | 2018-11-21 | 2020-10-16 | 南京北恒生物科技有限公司 | 修饰的t细胞及其用途 |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| CN111378624B (zh) * | 2018-12-29 | 2023-10-20 | 深圳市第三人民医院 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
| CN113966397A (zh) | 2019-03-08 | 2022-01-21 | 黑曜石疗法公司 | 人碳酸酐酶2组合物和用于可调调节的方法 |
| EP3733707A1 (en) | 2019-04-30 | 2020-11-04 | Celyad S.A. | Car t-cells targeting bcma and uses thereof |
| EP3983537A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CA3140668A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| EP3990491A1 (en) | 2019-06-26 | 2022-05-04 | Massachusetts Institute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| CN114450414A (zh) * | 2019-07-30 | 2022-05-06 | 大学健康网络 | T细胞受体及其使用方法 |
| CN114729028B (zh) * | 2019-08-29 | 2025-05-23 | 克莱格医学有限公司 | 抗移植反应的细胞和方法 |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| CA3163838A1 (en) | 2020-01-08 | 2021-07-15 | Vipin Suri | Compositions and methods for tunable regulation of transcription |
| CA3165346A1 (en) | 2020-01-23 | 2021-07-29 | George Q. Daley | Stroma-free t cell differentiation from human pluripotent stem cells |
| IL296242A (en) | 2020-03-10 | 2022-11-01 | Massachusetts Inst Technology | Methods for producing engineered memory-like nk cells and preparations containing them |
| JP2023517889A (ja) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法 |
| WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| WO2022005462A1 (en) * | 2020-06-30 | 2022-01-06 | Tr1X, Inc. | Poly-donor cd4+ t cells expressing il-10 and uses thereof |
| WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| WO2023201133A1 (en) | 2022-04-14 | 2023-10-19 | Board Of Regents Of The University Of Nebraska | Cell therapy for alzheimer's disease |
| JP2025531850A (ja) | 2022-09-08 | 2025-09-25 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ |
| CN115747166B (zh) * | 2022-10-13 | 2024-12-06 | 上海怡豪生物科技有限公司 | 一种通用型car-t细胞及其制备方法与应用 |
| CN117883478B (zh) * | 2024-03-14 | 2024-05-28 | 中国康复科学所(中国残联残疾预防与控制研究中心) | 非经典t细胞在制备治疗脊髓损伤的药物中的用途 |
Family Cites Families (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133433A (en) | 1984-07-27 | 2000-10-17 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
| US6242567B1 (en) | 1984-07-27 | 2001-06-05 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5667967A (en) | 1990-05-01 | 1997-09-16 | The Board Of Trustees Of The Leland Stanford Junior University | T-cell receptor varible transcripts as disease related markers |
| IL86278A (en) | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
| US6464978B1 (en) | 1989-03-21 | 2002-10-15 | The Immune Response Corporation | Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations |
| US5415874A (en) | 1989-10-31 | 1995-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Natural killer cell lines and clones with antigen specificity |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6416971B1 (en) | 1990-05-15 | 2002-07-09 | E.R. Squibb & Sons, Inc. | Soluble single chain T cell receptors |
| US6407221B1 (en) | 1990-12-14 | 2002-06-18 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| FR2672901B1 (fr) | 1991-02-15 | 1994-09-30 | Immunotech Sa | Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
| US7049136B2 (en) | 1991-03-07 | 2006-05-23 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| IL101147A (en) | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| JP3238447B2 (ja) | 1991-12-31 | 2001-12-17 | 株式会社エスアールエル | ヒト白血球株化細胞 |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| US6172278B1 (en) * | 1992-09-14 | 2001-01-09 | The General Hospital Corporation | Ikaros transgenic cells and mice |
| ATE177783T1 (de) | 1993-04-09 | 1999-04-15 | Pfizer | Ein menschlicher t-zell rezeptor der protein g- gekoppelte rezeptor familie |
| US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
| US5552300A (en) | 1994-01-13 | 1996-09-03 | T Cell Sciences, Inc. | T cell antigen receptor V region proteins and methods of preparation thereof |
| DE4408999A1 (de) | 1994-03-16 | 1995-09-28 | Braun Melsungen Ag | Humane T-Zellrezeptoren zur diagnostischen sowie therapeutischen Verwendung bei autoimmunem Diabetes mellitus |
| DE69528894T2 (de) | 1994-05-02 | 2003-03-27 | Bernd Groner | Bifunktionelles protein, herstellung und verwendung |
| US6083751A (en) | 1994-11-01 | 2000-07-04 | Targeted Genetics Corporation | Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells |
| GB9423085D0 (en) | 1994-11-16 | 1995-01-04 | Stringer Bradley M J | Targeted T lymphocytes |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6103521A (en) | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
| EP0871495B1 (en) | 1995-02-24 | 2005-06-15 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US5830755A (en) | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
| DE19540515C1 (de) | 1995-10-31 | 1997-02-06 | Boehringer Ingelheim Int | Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| WO1997032603A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| DE19625191A1 (de) | 1996-06-24 | 1998-01-02 | Boehringer Mannheim Gmbh | Nierenkarzinom-spezifische T-Zellen |
| EP0937095A4 (en) | 1996-10-25 | 1999-12-22 | Cell Genesys Inc | TARGETED CYTOLYSIS OF CANCER CELLS |
| US20040038894A1 (en) * | 1996-12-31 | 2004-02-26 | Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) | Compounds for modulating cell negative regulations and biological applications thereof |
| WO1998041613A1 (en) | 1997-03-14 | 1998-09-24 | Otten Gillis R | Targeted cytolysis of cancer cells |
| US20030060444A1 (en) | 1997-06-25 | 2003-03-27 | Celltech Therapeutics, Ltd. | Cell activation process and reagents therefor |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| IL127142A0 (en) | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
| JP2002533118A (ja) | 1998-12-29 | 2002-10-08 | ユニバーシティ オブ バーモント アンド ステイト アグリカルチャー カレッジ | Ｔ細胞レセプター使用を改変するためのｃｄ４０係合の使用 |
| EP1171596A1 (en) | 1999-04-16 | 2002-01-16 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| GB9925848D0 (en) | 1999-11-01 | 1999-12-29 | Celltech Therapeutics Ltd | Biological products |
| EP1118661A1 (en) | 2000-01-13 | 2001-07-25 | Het Nederlands Kanker Instituut | T cell receptor libraries |
| US6770749B2 (en) | 2000-02-22 | 2004-08-03 | City Of Hope | P53-specific T cell receptor for adoptive immunotherapy |
| IL136459A0 (en) | 2000-05-30 | 2001-06-14 | Galim Galil Immunology Ltd | Antibody library |
| US6953576B2 (en) | 2000-08-21 | 2005-10-11 | University Health Network | Method of modulating tumor immunity |
| EP1188825A1 (en) | 2000-09-18 | 2002-03-20 | Universiteit Leiden | T cell receptor transfer into a candidate effector cell or a precursor thereof |
| GB0025307D0 (en) | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| US20030068616A1 (en) * | 2000-12-07 | 2003-04-10 | Hanan Polansky | Drug discovery assays based on microcompetition for a limiting GABP complex |
| US20030069199A1 (en) * | 2000-12-07 | 2003-04-10 | Hanan Polansky | Treatment methods based on microcompetition for a limiting GABP complex |
| US20030104358A1 (en) * | 2000-12-07 | 2003-06-05 | Hanan Polansky | Diagnosis methods based on microcompetition for a limiting GABP complex |
| DK1409646T3 (da) | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
| IL141539A0 (en) | 2001-02-20 | 2002-03-10 | Yeda Res & Dev | Dna molecules and cells transfected therewith |
| US20040115198A1 (en) | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| CA2487779C (en) | 2001-06-05 | 2012-10-02 | Altor Bioscience Corporation | P53 binding t cell receptor molecules and uses thereof |
| WO2003015705A2 (en) | 2001-08-17 | 2003-02-27 | Roger Williams Hospital | In situ immunization |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| AU2003232075A1 (en) | 2002-05-07 | 2003-11-11 | The Children's Medical Center Corporation | Modified t lymphocytes and uses therefor |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2004022706A2 (en) | 2002-09-04 | 2004-03-18 | The Trustees Of The University Of Pennsylvania | Immune cell receptor ligand and immune cell receptor |
| DE10244457A1 (de) | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| DE10259713A1 (de) | 2002-12-19 | 2004-07-08 | Johannes-Gutenberg-Universität Mainz | Verfahren zur Expressionsstabilisierung und Verbesserung der spezifischen Effektorfunktion von Einzelketten-Antigenerkennenden genetischen Konstrukten (scARC) und entsprechend mutierten MDM2-Protein spezifischen scT-Zell Rezeptoren |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2005019420A2 (en) | 2003-08-20 | 2005-03-03 | St. Jude Children's Research Hospital | Chimeric receptors with disrupted dileucine motifs |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US20050238626A1 (en) | 2004-04-01 | 2005-10-27 | Lili Yang | Antigen specific T cell therapy |
| EP1756278B1 (en) | 2004-05-19 | 2008-09-17 | MediGene Ltd. | Method of improving t cell receptors |
| ATE417065T1 (de) | 2004-05-19 | 2008-12-15 | Medigene Ltd | Hochaffiner ny-eso-t-zellen-rezeptor |
| DK1791865T3 (da) | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Celler der udtrykker en modificeret T-cellerecptor |
| JP2008504821A (ja) * | 2004-07-01 | 2008-02-21 | バイレクシス コーポレイション | ベクター・パッケージング細胞系列 |
| DK2112162T3 (da) | 2004-07-10 | 2015-02-23 | Fox Chase Cancer Ct | Genetisk modificerede humane naturlige dræbercellelinjer |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| WO2006036445A2 (en) * | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
| WO2007044033A2 (en) | 2004-12-07 | 2007-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen |
| EP1827604B1 (en) | 2004-12-10 | 2019-11-20 | Peter MacCallum Cancer Institute | Methods and compositions for adoptive immunotherapy |
| CA2602463C (en) | 2005-04-01 | 2018-09-04 | Avidex Ltd | High affinity hiv t cell receptors |
| GB0524477D0 (en) | 2005-11-30 | 2006-01-11 | Avidex Ltd | Isolated T cell receptors which specifically bind to vygfvracl-hla-24 |
| GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| JP2006345852A (ja) * | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| PT2327763T (pt) | 2005-08-05 | 2018-05-11 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Geração de células t específicas de antigénios |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| EP1795599A1 (en) | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
| US7820174B2 (en) | 2006-02-24 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| EP2016102B1 (en) | 2006-05-03 | 2012-03-21 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | Chimeric t cell receptors and related materials and methods of use |
| EP1870418A1 (en) | 2006-06-20 | 2007-12-26 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Allorestricted peptide-specific T cells |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| EP1878744A1 (en) | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
| DE102006041455B4 (de) | 2006-09-04 | 2011-07-28 | Johannes-Gutenberg-Universität Mainz, 55122 | Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| EP1932537A1 (en) | 2006-12-12 | 2008-06-18 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Expression of transgenic T cell receptors in LAK-T cells |
| US7508404B2 (en) | 2006-12-21 | 2009-03-24 | Eastman Kodak Company | Thermal printer with two print heads |
| US8216565B2 (en) | 2007-01-12 | 2012-07-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | GP100-specific T cell receptors and related materials and methods of use |
| DK2126054T3 (en) * | 2007-01-31 | 2016-10-03 | Yeda Res & Dev | REROUTED, GENETICALLY MODIFIED regulatory T cells and their use for suppressing autoimmune inflammatory disease AND |
| DK2856876T3 (en) | 2007-03-30 | 2018-04-03 | Memorial Sloan Kettering Cancer Center | Constitutive expression of co-stimulatory ligands on adoptively transmitted T lymphocytes |
| US20110213288A1 (en) * | 2007-04-23 | 2011-09-01 | The Board Of Regents, The University Of Texas System | Device And Method For Transfecting Cells For Therapeutic Uses |
| JP5271901B2 (ja) | 2007-06-11 | 2013-08-21 | タカラバイオ株式会社 | 特異的遺伝子発現方法 |
| EA201000343A1 (ru) | 2007-10-04 | 2011-10-31 | Займодженетикс, Инк. | ЧЛЕН СЕМЕЙСТВА B7, zB7H6 И РОДСТВЕННЫЕ КОМПОЗИЦИИ И СПОСОБЫ |
| GB0721686D0 (en) | 2007-11-05 | 2007-12-12 | Medinnova As | Polypeptides |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| WO2010012829A1 (en) | 2008-07-31 | 2010-02-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Her2/neu specific t cell receptors |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| EP2362877A4 (en) | 2008-11-06 | 2012-05-09 | Univ Columbia | POLYNUCLEOTIDES CODING FOR HUMAN TRIM-CYP FUSION POLYPEPTIDE, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF |
| EP2186825A1 (en) | 2008-11-13 | 2010-05-19 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Human-derived T cell receptors |
| JP6069755B2 (ja) | 2008-11-24 | 2017-02-01 | ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー | 高親和性ｔ細胞受容体およびその用途 |
| WO2010088160A1 (en) | 2009-01-28 | 2010-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| FR2941858B1 (fr) | 2009-02-10 | 2011-03-11 | Charam Khosrvaninejad | Dispositif chirurgical apte a realiser la protection temporaire d'une anastomose |
| WO2010107400A1 (en) | 2009-03-20 | 2010-09-23 | Agency For Science, Technology And Research | Genetically modified animal and method of obtaining the same |
| US20120142764A1 (en) * | 2009-06-05 | 2012-06-07 | Dai-Wu Seol | Multi-Cistronic shRNA Expression Cassette for Suppressing Single or Multiple Target Genes |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US10138276B2 (en) * | 2009-09-30 | 2018-11-27 | Signablok, Inc. | Inhibition of TCR signaling with peptide variants |
| AU2010301042B2 (en) | 2009-10-01 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| WO2011064664A2 (en) | 2009-11-24 | 2011-06-03 | Chrontech Pharma Ab | T cell receptors specific for immunodominant ctl epitopes of hcv |
| HRP20141170T1 (hr) | 2009-12-09 | 2015-01-30 | Institut National de la Santé et de la Recherche Médicale | Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe |
| US20120294857A1 (en) | 2010-01-11 | 2012-11-22 | Trustees Of Dartmouth College | Monomeric Bi-Specific Fusion Protein |
| JP6050230B2 (ja) * | 2010-07-21 | 2016-12-21 | サンガモ バイオサイエンシーズ， インコーポレイテッド | Ｈｌａ遺伝子座の修飾のための方法及び組成物 |
| WO2012013913A1 (en) | 2010-07-28 | 2012-02-02 | Immunocore Ltd | T cell receptors |
| US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| MX2013004792A (es) | 2010-10-27 | 2013-08-27 | Baylor College Medicine | Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas. |
| US9777332B2 (en) | 2011-03-31 | 2017-10-03 | St. Jude Children's Research Hospital | Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia |
| WO2013033626A2 (en) * | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| US10391126B2 (en) * | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| WO2013096709A2 (en) * | 2011-12-21 | 2013-06-27 | modeRNA Therapeutics | Methods of increasing the viability or longevity of an organ or organ explant |
| HUE064187T2 (hu) * | 2012-05-25 | 2024-02-28 | Cellectis | Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására |
| WO2015017755A1 (en) | 2013-08-02 | 2015-02-05 | The Regents Of The University Of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| CN106132423B (zh) * | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| IL303905A (en) * | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| AR105433A1 (es) * | 2015-07-21 | 2017-10-04 | Novartis Ag | Métodos para mejorar la eficacia y expansión de las células inmunes |
| BR112018071153A2 (pt) * | 2016-04-15 | 2019-04-16 | Immunext, Inc. | anticorpos anti-vista humano e uso dos mesmos |
| US12060394B2 (en) * | 2016-04-28 | 2024-08-13 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
| CN110831619A (zh) * | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 具有增强功效的生物标志和car t细胞疗法 |
| EP3630980B1 (en) * | 2017-06-01 | 2023-11-01 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cell preparation and uses thereof |
| AU2018313939A1 (en) * | 2017-08-10 | 2020-02-06 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
| CN111225670A (zh) * | 2017-09-08 | 2020-06-02 | 大学健康网络 | 抑制Polo样激酶4的组合疗法 |
| KR102823603B1 (ko) * | 2017-10-12 | 2025-06-23 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 면역요법을 위한 t 세포 수용체 |
| US12280092B2 (en) * | 2018-01-05 | 2025-04-22 | Nantbio, Inc. | Reprogrammed T cell-like NK cells |
| SG11202012253WA (en) * | 2018-07-26 | 2021-01-28 | Nanjing Legend Biotech Co Ltd | Nef-containing t cells and methods of producing thereof |
| WO2020028444A1 (en) * | 2018-07-30 | 2020-02-06 | University Of Southern California | Improving the efficacy and safety of adoptive cellular therapies |
| EP4198057A1 (en) * | 2018-12-05 | 2023-06-21 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for cancer immunotherapy |
| US11858977B2 (en) * | 2019-10-24 | 2024-01-02 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified TCR and uses thereof |
-
2012
- 2012-04-30 US US13/459,664 patent/US9273283B2/en active Active
-
2013
- 2013-04-30 RU RU2014148136A patent/RU2653761C2/ru active
- 2013-04-30 BR BR112014027155-0A patent/BR112014027155B1/pt active IP Right Grant
- 2013-04-30 CN CN201380034582.9A patent/CN104395463B/zh active Active
- 2013-04-30 WO PCT/US2013/038921 patent/WO2013166051A1/en not_active Ceased
- 2013-04-30 CN CN201810086091.3A patent/CN108384758B/zh active Active
- 2013-04-30 EP EP13784744.8A patent/EP2844742B1/en active Active
- 2013-04-30 AU AU2013256424A patent/AU2013256424B2/en active Active
- 2013-04-30 ES ES18198906T patent/ES2878724T3/es active Active
- 2013-04-30 MX MX2019007492A patent/MX386776B/es unknown
- 2013-04-30 CN CN201810720554.7A patent/CN108795875B/zh active Active
- 2013-04-30 EP EP18198906.2A patent/EP3447125B1/en active Active
- 2013-04-30 MX MX2014013118A patent/MX366018B/es active IP Right Grant
- 2013-04-30 ES ES13784744T patent/ES2711629T3/es active Active
- 2013-04-30 EP EP21158803.3A patent/EP3904503A1/en active Pending
- 2013-04-30 JP JP2015510393A patent/JP6411328B2/ja active Active
- 2013-04-30 CA CA2871955A patent/CA2871955C/en active Active
-
2016
- 2016-01-22 US US15/003,968 patent/US9663763B2/en active Active
-
2017
- 2017-04-10 US US15/483,704 patent/US11136549B2/en active Active
-
2018
- 2018-05-15 JP JP2018093635A patent/JP6805204B2/ja active Active
- 2018-10-26 AU AU2018253624A patent/AU2018253624B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX386776B (es) | Composiciones de células t deficientes del receptor de células t. | |
| MX2023001878A (es) | Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t. | |
| WO2011059836A8 (en) | T cell receptor-deficient t cell compositions | |
| TN2014000298A1 (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
| WO2013033626A3 (en) | Nkp30 receptor targeted therapeutics | |
| MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
| PH12015500963A1 (en) | Tricyclic fused thiophene derivatives as jak inhibitors | |
| PH12014502577A1 (en) | Compositions comprising an anti-pdgf aptamer and a vegf antagonist | |
| PH12014502496B1 (en) | Bicyclically substituted uracils and the use thereof | |
| PH12015500114A1 (en) | HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF | |
| EP2523678A4 (en) | WNT ANTAGONISTS AND TREATMENT AND SCREENING METHOD THEREFOR | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| PH12015501043A1 (en) | Novel compounds | |
| NI201000214A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor de la histamina h4. | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| UY35370A (es) | Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4 | |
| TR201909158T4 (tr) | siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları. | |
| BR112016029632A2 (pt) | derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase | |
| MX2017001293A (es) | Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino. | |
| MX2013004062A (es) | Analogos de ciclosporina. | |
| EA201590503A1 (ru) | Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями | |
| MX362854B (es) | Siarn y su uso en los metodos y composiciones para el tratamiento y/o prevencion de enfermedades de los ojos. | |
| HK1213175A1 (zh) | Tspo介导的疾病和/或病症的治疗和/或预防 | |
| MX2015016603A (es) | Composiciones de corticosteroides. | |
| UY34594A (es) | Derivados heterocíclicos bicíclicos, su preparación y su aplicación en terapéutica |